Shots:
- Assessing PF’3944 (QW titration to QM) in obese/overweight pts without T2D, the trial randomized pts to Arm 1 (0.4mg QW/ 0.8mg QW/ 3.2mg QM), Arm 2 (0.8mg QW/ 3.2mg QM), Arm 3 (0.4mg QW/ 0.8mg QW/ 1.2mg QW/ 4.8mg QM), Arm 4 (0.6mg QW/ 1.2mg QW/ 4.8mg QM), or Arm 5 (PBO)
- Trial met its 1EP, showing up to 12.3% PBO-adjusted weight loss at wk. 28 (efficacy estimand); Arms 1 & 3 achieved 10% & 12.3% loss, supporting their selection for P-III, with sustained, non-plateauing weight reduction after switching to QM dosing; data to be presented at ADA’26
- Also, Pfizer is planning an expansive obesity program with 20+ trials in 2026, incl. 10 P-III trials for PF’3944 such as VESPER-4 (QW, no T2D), VESPER-5 (QW, with T2D), VESPER-6 (QM), & ≥7 additional P-III trials targeting comorbidities & patient optionality & access
Ref: Pfizer | Image: Pfizer | Press Release
Related News: Pfizer Signs ~$530M Deal to Use Novavax’s Adjuvant in Product Development
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
